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IMPORTANCE Five to ten percent of individuals with latent tuberculosis infection (LTBI)
progress to active tuberculosis (TB) disease. Identifying and treating LTBI is a key component
of the strategy for reducing the burden of TB disease.
OBJECTIVE To review the evidence about targeted screening and treatment for LTBI among
adults in primary care settings to support the US Preventive Services Task Force in updating
its 1996 recommendation.
DATA SOURCES MEDLINE, Cochrane Library, and trial registries, searched through August 3,
2015; references from pertinent articles; and experts. Literature surveillance was conducted
throughMay 31, 2016.
STUDY SELECTION English-language studies of LTBI screening, LTBI treatment with
recommended pharmacotherapy, or accuracy of the tuberculin skin test (TST) or
interferon-gamma release assays (IGRAs). Studies of individuals for whom LTBI screening and
treatment is part of public health surveillance or disease management were excluded.
DATA EXTRACTION AND SYNTHESIS Two investigators independently reviewed abstracts and
full-text articles. When at least 3 similar studies were available, random-effects meta-analysis
was used to generate pooled estimates of outcomes.
MAIN OUTCOMES ANDMEASURES Sensitivity, specificity, reliability, active TB disease,
mortality, hepatotoxicity, and other harms.
RESULTS The review included 72 studies (n = 51 711). No studies evaluated benefits and harms
of screening compared with no screening. Pooled estimates for sensitivity of the TST at both
5-mm and 10-mm induration thresholds were 0.79 (5-mm: 95% CI, 0.69-0.89 [8 studies,
n = 803]; 10mm: 95% CI, 0.71-0.87 [11 studies; n = 988]), and those for IGRAs ranged from
0.77 to 0.90 (57 studies; n = 4378). Pooled estimates for specificity of the TST at the 10-mm
and 15-mm thresholds and for IGRAs ranged from0.95 to 0.99 (34 studies; n = 23 853).
A randomized clinical trial (RCT) of 24 weeks of isoniazid in individuals with pulmonary
fibrotic lesions and LTBI (n = 27 830) found a reduction in absolute risk of active TB at 5 years
from 1.4% to 0.5% (relative risk [RR], 0.35 [95% CI, 0.24-0.52]) and an increase in absolute
risk for hepatoxicity from 0.1% to 0.5% (RR, 4.59 [95% CI, 2.03-10.39]) for 24 weeks of daily
isoniazid compared with placebo. An RCT (n = 6886) found that 3 months of once-weekly
rifapentine plus isoniazid was noninferior to 9months of isoniazid alone for preventing active
TB. The risk difference for hepatoxicity comparing isoniazid with rifampin ranged from 3% to
7%, with a pooled RR of 3.29 (95% CI, 1.72-6.28 [3 RCTs; n = 1327]).
CONCLUSIONS AND RELEVANCE No studies evaluated the benefits and harms of screening
compared with no screening. Both the TST and IGRAs are moderately sensitive and highly
specific within countries with low TB burden. Treatment reduced the risk of active TB among
the populations included in this review. Isoniazid is associated with higher rates of
hepatotoxicity than placebo or rifampin.
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P revention of active tuberculosis (TB) by treating latenttuberculosis infection (LTBI) is a major goal of the strategyfor eliminating TB.1,2 Estimating the prevalence of LTBI is
challenging because there is no direct test for latent infection, but
US national survey data suggest a population prevalence of 4.7%
(95% CI, 3.4%-6.3%) for the overall US population and 20.5%
(95% CI, 16.1%-25.8%) for the foreign-born US population, based
on a positive tuberculin skin test (TST) result.3 Five percent to 10%
of immunocompetent individuals with a positive TST result will
develop active TB disease in their lifetime.4 In developed countries
with a low prevalence of TB, LTBI screening is recommended by
the World Health Organization, American Thoracic Society, Infec-
tious Diseases Society of America, and the Centers for Disease Con-
trol and Prevention (CDC) only for high-risk groups andwhen treat-
ment is feasible.5,6 Current screening tests for LTBI include the TST
and interferon-gamma release assays (IGRAs). Individuals who
screen positive are generally offered preventive treatment (eTable
1 in the Supplement) after active infection has been excluded.7
In 1996, the US Preventive Services Task Force (USPSTF) rec-
ommended screeningwith the TST for asymptomatic, high-risk in-
dividuals (A recommendation). To inform an updated recommen-
dation,we reviewed theevidenceon test accuracyandbenefits and
harms of screening and treatment for LTBI in settings and popula-
tions relevant to US primary care.
Methods
Scope of the Review
Detailed methods are available in the full evidence report at
http://www.uspreventiveservicestaskforce.org/Page/Document
/final-evidence-review157/latent-tuberculosis-infection-screening.
The analytic framework and key questions that guided the review
are shown in Figure 1.
Data Sources and Searches
PubMed/MEDLINE and the Cochrane Library were searched for
English-language articles published from database inception
through August 3, 2015. The search strategies for these databases
are listed in the eMethods in the Supplement. ClinicalTrials.gov and
the World Health Organization International Clinical Trials Registry
Platform were also searched for unpublished literature. To supple-
ment electronic searches, the reference lists of pertinent articles
and all studies suggested by reviewers or comments received dur-
ing public commenting periods were reviewed. Since August 2015,
ongoing surveillance has been conducted through article alerts and
targeted searches of high-impact journals to identify major studies
published in the interim that may affect the conclusions or under-
standing of the evidence and therefore the related USPSTF recom-
mendation. The last surveillance was conducted on May 31, 2016,
and no new studies were identified.
Study Selection
Two investigators independently reviewed titles, abstracts, and
full-text articles using prespecified inclusion criteria for each key
question (KQ) (eTable 2 in the Supplement). Disagreements
about inclusion were resolved by discussion. Only studies rated as
of fair or good quality were included. For the overarching ques-
tion regarding direct evidence of benefits of screening (KQ1), only
randomized clinical trials (RCTs) or prospective cohort studies
that compared screening with no screening in primary care set-
tings and focused on asymptomatic adults belonging to popula-
tions at increased risk for developing active TB were eligible. Pri-
mary care was broadly defined to include public health settings or
specialized clinics providing primary care functions (eg, prison
clinics). Studies in which more than 25% of the study population
were younger than 18 years or were known to be human immuno-
deficiency virus (HIV) positive were excluded, unless results were
stratified by these characteristics. Studies on close contacts of
individuals with active TB were excluded because testing and
treatment of such populations is considered a public health sur-
veillance activity. Studies of individuals with underlying immuno-
suppression and for whom LTBI screening and treatment would
be part of disease management were also excluded, for example,
studies of individuals beginning treatment with tumor necrosis
factor–alpha inhibitors. Other populations at increased risk were
included, such as persons who had previously received the bacil-
lus Calmette–Guérin (BCG) vaccination, injection drug users, per-
sons who were homeless or residing in homeless shelters, former
prisoners, persons born in or former residents of countries with
high TB prevalence, persons who worked with such individuals,
and persons with a documented increased risk for progression
from LTBI to active TB.
For screening test accuracyand reliability (KQ2), studiesassess-
ing theTSTusing theMantouxmethodand3 IGRAswere included.8
Because there is no direct reference test for latent infection,we re-
lied on studies of individuals with bacteriologically confirmed ac-
tive TB conducted in any country or setting for sensitivity and on
studies of healthy participants at low risk for TB and TB exposure
thatwere conducted in countries not considered as having high TB
burden for specificity.8,9 Reliability was defined as the degree to
which a test provided stable and consistent results, including out-
comes such as test-retest reliability, interrater reliability, and inter-
laboratory reliability.
To review the benefits (KQ3) and harms (KQ5) of treatment,
RCTs of individuals with LTBI that compared a CDC-recommended
treatment (medication, dose, and duration) with placebo, delayed
treatment, no treatment, or another CDC-recommended treat-
mentwere included. Forharmsof treatment (KQ5), prospective co-
hort studies and case-control studies were also eligible. For harms
associatedwithscreening (KQ4), systematic reviews,RCTs, andpro-
spectivecohort studies reporting false-positive results leading toun-
necessary testing (eg, chest radiography) or treatment, labeling,
stigma, anxiety, or cellulitis were eligible.
Except for studies of screening test accuracy and reliability
(KQ2), studiesconducted incountries categorizedasanythingother
than“veryhigh”ontheUnitedNationsHumanDevelopment Index10
were excluded.
Data Extraction andQuality Assessment
For each included study, one investigator extracted information
about design, population, tests or treatments used, and outcomes
(eg, sensitivity, specificity, active TB), and a second investigator re-
viewed for completeness and accuracy. Two independent investi-
gators assessed thequalityof eachstudyasgood, fair, orpoor, using
predefined criteria developed by the USPSTF and adapted for this
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topic (eTable 3 in the Supplement).11 Individual study quality rat-
ings are provided in eTables 4-7 in the Supplement.
Data Synthesis and Analysis
Findings for each question are summarized in tabular andnarrative
form. To determine whether meta-analyses were appropriate, the
number of studies available and the clinical and methodological
heterogeneity of the studies following established guidance were
assessed.12 To do this, the populations, similarities and differences
in screening tests or treatments used, and similarities in outcomes
and timing of measured outcomes, were qualitatively assessed.
When at least 3 similar studies were available, quantitative synthe-
sis was conducted with random-effects models using the inverse-
variance weighted method (DerSimonian and Laird) to determine
pooled estimates.12,13 Statistical heterogeneity was assessed using
the I2 statistic.Results forbenefits andharmsof treatment (KQ3and
KQ5)were considered statistically significant if theP valuewas less
than .05basedon2-sidedtesting.Allquantitativeanalyseswerecon-
ducted using Stata version 13.1 (StataCorp).14
Sensitivity analyses for screening test accuracy (KQ2) added in
19 studies rated as poor quality to determine whether inclusion of
such studies would have altered conclusions. For benefits (KQ3)
and harms (KQ5) of treatment, sensitivity analyses also added
6 RCTs comparing isoniazid with placebo that were either poor
quality, did not meet all of the inclusion criteria, or both, because
they used a longer duration of treatment than is currently recom-
mended (eg, they used 1 year of isoniazid15-19 or 3 months of
isoniazid20); some also used lower or higher doses than currently
recommended.16,17 For RCTs to be included in sensitivity analyses,
they either confirmedLTBI for participants to be eligible (eg, by en-
rolling only those who were TST positive), reported data for those
with confirmed LTBI (eg, for the TST-positive subset of partici-
pants), or the vast majority of participants (more than 75%) were
TST positive.
Figure 1. Analytic Framework and Key Questions
Key questions
Is there direct evidence that targeted screening for latent tuberculosis infection (LTBI) in primary care settings in asymptomatic adults at increased risk
for developing active tuberculosis disease (eg, individuals in populations with a high prevalence of active TB disease or with documented increased risk
for progression from LTBI to active TB disease) improves quality of life, or reduces active TB disease incidence, or reduces transmission of TB, or
reduces disease-specific or overall mortality?
1
Are there harms associated with treatment for LTBI with CDC-recommended pharmacotherapy regimens?5
a. What is the accuracy and reliability of the TST or the interferon-gamma release assay (IGRA) for screening asymptomatic adults who are at increased
risk for developing active TB disease?
b. What is the accuracy and reliability of sequential screening strategies that include both TST and IGRA testing in asymptomatic adults who are at
increased risk for developing active TB disease? 
2
Does treatment of LTBI with CDC-recommended pharmacotherapy regimens improve quality of life or reduce progression to active TB disease,
or reduce transmission of TB, or reduce disease-specific or overall mortality?
3
Are there harms associated with screening for LTBI?
a. Do these harms differ by screening method or strategy? 
b. Do these harms differ by population?
4
Screening
Tuberculin skin test
or interferon-gamma
release assay
Reduced tuberculosis
transmission
Improved quality of life
Reduced tuberculosis disease
or overall mortality
Reduced incidence of active
tuberculosis disease
1
Asymptomatic adults
belonging to populations 
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Treatment
2 3
Harms of
screening 
Harms of
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54
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an
analytic framework to visually display the key questions that the reviewwill
address to allow the USPSTF to evaluate the effectiveness and safety of a
preventive service. The questions are depicted by linkages that relate
interventions and outcomes. CDC indicates Centers for Disease Control and
Prevention. Further details are available from the USPSTF procedure manual.106
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For all quantitative syntheses, sensitivity analyses were con-
ducted usingmaximum likelihood random-effects (KQ2) or profile
likelihood random-effects methods (KQs 3 and 5) because
DerSimonianandLairdmodelsmaynotperformwellwhenfewstud-
ies are included.21-25 Results were essentially the same as for those
usingDerSimonianandLaird random-effectsmodels,with somemi-
nor variation in width of confidence intervals for some estimates,
and thus are not reported further.
Results
Study selection included reviewing 4408 titles and abstracts and
614 full-text articles (Figure 2). Of the 72 fair- or good-quality stud-
ies thatmet inclusioncriteria (n = 51 711),67wereobservational stud-
ies of screening test characteristics (KQ2). Five studies were RCTs
focusedon thebenefits (KQ3) or harms (KQ5) of pharmacotherapy
for LTBI.Noeligible studies forKQ1 (direct evidenceof screening for
LTBI) or KQ4 (harms of screening) were identified.
Benefits of Screening
KeyQuestion 1. Is theredirect evidence that targeted screening for
LTBI in primary care settings in asymptomatic adults at increased
risk for developing active TB improves quality of life or reduces
active TB disease, transmission of TB, or disease specific or over-
all mortality?
No eligible studies were identified.
Accuracy and Reliability of Screening Tests
Key Question 2.What is the accuracy and reliability of the TST or
IGRA (KQ2a) or sequential screening strategies (KQ2b) for screen-
ingasymptomatic adultswhoareat increased risk fordevelopingac-
tive TB disease?
No eligible studies evaluating sequential screening strategies
were identified. Fifty studies (n = 4167) related to the sensitivity of
theTSTor IGRA testswere identified; detailed individual study char-
acteristics are provided in eTables 8 and 9 in the Supplement. Eight
studies were conducted in high TB-burden countries,26-33 29 were
conductedincountrieswith intermediateTBburden,34-62and10were
conducted in countries with low TB burden,63-72 including 4 in the
United States. Threemultinational studieswere conducted in coun-
trieswith amix of low and intermediate TBburden.73-75 In 3 studies,
fewer than 25% of the participants were BCG vaccinated.28,30,72
Thirteen studies included study populations that were between
25%and75%vaccinated,27,29,34,36,38,39,43,56,58,59,65,70,71 and12stud-
ies included study populations that had more than 75% of partici-
pants vaccinated.26,32,33,40-42,45,51,52,61,66,74 Twenty-two studies did
not report the BCG vaccination prevalence in the study population.
Pooled estimates were calculated for sensitivity of the TST by
indurationthresholdandof IGRAsbyassay (Table 1).Thepooledsen-
sitivity for the TSTwith a 5-mm threshold was 0.79 (95%CI, 0.69-
0.89; I2 = 94.6%[8studies;n = 803]); for the10-mmthreshold,0.79
(95%CI,0.71-0.87; I2 = 91.4%[11 studies; n = 988]); and for 15-mm
threshold,0.52 (95%CI,0.35-0.68, I2 = 95.5%[7studies;n = 740])
(eFigure 1 in the Supplement). For the T-SPOT.TB IGRA, there was
Figure 2. Literature FlowDiagram
67 Studies included for KQ2
9 For reliability
 50 For sensitivity
18 For specificity
0 Studies included for KQ1 0 Studies included for KQ43 Studies included for KQ3 5 Studies included for KQ5
4369 Records identified through literature database
searches (after duplicates removed)
39 Records identified through other sources
(eg, reference lists, personal communications)
4408 Records screened
3794 Records excluded
541 Excludeda
41 Ineligible or no comparator(s)
19 Not original research
2 No full text
8 Ineligible setting
267 Ineligible population(s)
15 Poor quality
36 Ineligible study design
 63 Ineligible or no outcomes
90 Ineligible or no screening
or intervention(s)
72 Fair- or good-quality studies included
(73 articles)
614 Full-text articles assessed for eligibility
a Nineteen studies that were poor quality, ineligible, or both were excluded but used in sensitivity analyses.
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nodifference in estimates basedonwhether theUSFoodandDrug
Administration or European threshold for a positive test was used,
so all studies were combined for a pooled estimate of 0.90 (95%
CI, 0.87-0.93; I2 = 63.6% [16 studies; n = 984]) (eFigure 2 in the
Supplement). The pooled estimate for sensitivity of the
QuantiFERONTBGold IGRAwas0.77 (95%CI,0.74-0.81; I2 = 55.3%
[17studies;n = 1073])andof theQuantiFERONTBGold In-Tube IGRA
was 0.80 (95% CI, 0.77-0.84; I2 = 74.3% [24 studies; n = 2321])
(eFigure 2 in the Supplement). The percentage of IGRA tests with
indeterminate results ranged from 3% to 7% in studies reporting
this information.
Because there was moderate to substantial statistical hetero-
geneity, results for all tests were stratified based on factors consis-
tently reported across studies that could affect the accuracy of the
test, includingwhether testingoccurredafter anti-TB treatmenthad
been started, theTBburdenof the countrywhere study tookplace,
and BCG vaccination prevalence among the study population. De-
tailed findings related to these analyses are in the full evidence re-
port. For some tests, estimates for sensitivity were higher in coun-
trieswith lowTBburdencomparedwithcountrieswith intermediate
orhighTBburden.Forexample, sensitivity for theTSTat the 10-mm
induration threshold was 0.88 (95% CI, 0.76-0.99 [3 studies;
n = 424]) in low-burden countries, comparedwith0.72 in interme-
diate-burden countries (95% CI, 0.65-0.79 [6 studies; n = 416]).
Eighteen studies related to the specificity of the TST or IGRA
testswere identified (n = 10693); detailed individual study charac-
teristics are provided in eTables 10 and 11 in the Supplement. Four-
teenof the 18studiesevaluatingspecificitywereconducted incoun-
tries with low TB burden (10 were in the United States).64,65,76-87
BCG vaccination rates were more than 75% in 4 studies,40,45,58,76
less than 5% in 9 studies,64,65,77,78,80,82-85 and not reported in 5
studies.73,79,86-88 Pooled estimates were calculated for specificity
of the TST by test threshold and of IGRAs by assay (Table 1).
The pooled specificity for the TSTwith a 10-mm thresholdwas
0.97 (95%CI, 0.96-0.99; I2 = 94.3% [9 studies; n = 9651]); for the
15-mm threshold, 0.99 (95%CI, 0.98-0.99; I2 = 91.7% [12 studies;
n = 9640]); individual study estimates are provided in eFigure 3 in
theSupplement. Thepooledestimate for specificitywas0.95 (95%
CI, 0.92-0.98; I2 = 79.1% [5 studies; n = 1810]) for the T-SPOT TB
IGRA; 0.98 (95% CI, 0.90-1.0 [4 studies; n = 699]) for the
QuantiFERON TB Gold IGRA; and 0.97 (95% CI, 0.94-0.99;
I2 = 93.4% [4 studies; n = 2053]) for theQuantiFERONTBGold In-
Tube IGRA; individual study estimates are provided in eFigure 3 in
the Supplement. The percentage of IGRA tests with indeterminate
results ranged from 0% to 3% in studies reporting this informa-
tion. Because of substantial heterogeneity, results were stratified
based on country TB burden and BCG vaccination rates. Across all
tests, specificity was substantially lower in countries with interme-
diate TB burden than in those with low TB burden. Although the
populations of studies conducted in intermediate-burden coun-
tries also hadhighprevalence of BCGvaccination, the available evi-
dencedidnotallowdefinitiveconclusionsabout the influenceofBCG
vaccination on specificity estimates because BCG vaccination sta-
tus was not consistently reported across studies.
Nine studies (n = 4079)were identified that assessed the reli-
ability for at least 1 of the included screening tests.45,80,84,85,89-93
Individual study characteristics are provided in eTable 12 in the
Supplement.Overall reliability variedby test andby typeof reliabil-
Table 1. Summary of Pooled Test Characteristics (Key Question 2) for Various Thresholds of Tuberculin Skin Test and Interferon-Gamma Release
Assays Among PatientsWith Bacteriologically Confirmed Tuberculosis (Sensitivity) and Healthy ParticipantsWithout Tuberculosis Risks
or Exposures (Specificity)
Test
Sensitivity Specificity
No. of
Studies
Participants,
No.
Pooled Estimate (95%
CI) I2, %
No. of
Studies
Participants,
No.
Pooled Estimate (95%
CI)a I2, %
TST induration
threshold, mm
5 8 803 0.79 (0.69-0.89) 94.6 4 4740 0.30 (0.19-0.44)
NA
284865 0.95 (0.94-0.96)
175076 0.94 (0.92-0.95)
55177 0.97 (0.95-0.98)
10 11 988 0.79 (0.71-0.87) 91.4 9b 9651 0.97 (0.96-0.99) 94.3
15 7 740 0.52 (0.35-0.68) 95.5 12 9640 0.99 (0.98-0.99) 91.7
IGRA
T-SPOT.TB 16c 984 0.90 (0.87-0.93) 63.6 5 1810 0.95 (0.92-0.98) 79.1
QuantiFERON TB Gold 17 1073 0.77 (0.74-0.81) 55.3 4 699 0.98 (0.90-1.0)d NAd
QuantiFERON TB Gold
In-Tube
24 2321 0.80 (0.77-0.84) 74.3 4 2053 0.97 (0.94-0.99) 93.4
Abbreviations: I2, proportion of variation in study estimates due to
heterogeneity; IGRA, interferon-gamma release assay; NA, not applicable;
TST, tuberculin skin test.
a Individual study estimates are reported for 5-mm TST induration threshold
(studies were not pooled for this outcome because 1 study estimate from
a country with intermediate tuberculosis burden wasmuch lower than
the estimates from countries with low tuberculosis burden).
bOne study78 could not be included in the DerSimonian-Laird pooled estimate
owing to a point estimate of 1.0 for specificity (95% CI, 0.99-1.00). The
estimate using themaximum likelihood approach, which can accommodate
point estimates of 1.0, was similar (pooled specificity, 0.97 [95% CI,
0.93-0.99]).
c One study69 could not be included in the pooled estimate owing to a point
estimate of 1.0 for sensitivity (95% CI, 0.69-1.0). The estimate using the
maximum likelihood approach, which can accommodate point estimates of
1.0, was similar (pooled sensitivity, 0.90 [95% CI, 0.86-0.93]).
d Pooled estimate is frommaximum likelihood random-effects model, because 2
studies included point estimates of 1.0 for specificity. The I2 statistic is not
calculated when using this method.
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ity outcome. Three studies (n = 1826,80 n = 1189,85 and n = 12784)
measured the interrater reliability for TST results by reporting the
κ statistic for agreement by TST reaction size; results ranged from
0.55 to 0.79, indicating moderate to substantial agreement be-
tween 2 observers. One study (n = 91) evaluated the interlabora-
tory reliability of the QuantiFERON TB Gold In-Tube IGRA by send-
ing 3 blood specimens from each participant to 3 different
laboratoriesnotedtohaveextensiveexperienceandproficiencywith
IGRA testing and interpretation.91 Across all 3 laboratories, 7.7%of
participants had discordant results (none had indeterminate re-
sults); κ values of pairwise laboratory sample comparisons ranged
from0.87 to 0.93.91 One study (n = 130) assessed the reliability of
IGRA results by processing 2 blood samples from each study par-
ticipant (using the same laboratory and same type of test interpre-
tation); 5.8% of participants had discordant results for the
QuantiFERON TB Gold In-Tube IGRA, and 6.5% had discordant re-
sults for T-SPOT.TB.89 Additional reliability results are provided in
the eResults in the Supplement.
Benefits of Treatment
Key Question 3. Does treatment of LTBI with CDC-recommended
pharmacotherapy improve quality of life or reduce progression to
active TB, TB transmission, or disease-specific or overall mortality?
Study characteristics of trials evaluating the benefits of treat-
ment are reported in Table 2. Three RCTs that evaluated the ben-
efits of treatment for LTBIwere included; 1 compared isoniazidwith
placebo (n = 27 830)97; 1 compared rifampin with isoniazid
(n = 847)95; and 1 compared rifapentine plus isoniazid with isonia-
zidalone (n = 6886).96Nostudies reportedbenefits related toqual-
ity of life or TB transmission.
The International Union Against Tuberculosis (IUAT) trial ran-
domized 27830 adults with fibrotic pulmonary lesions and a 6-mm
or greater Mantoux TST induration, but without active TB or previ-
ous anti-TB treatment, to 4 groups: placebo or isoniazid (300 mg
daily) for 12 weeks, 24 weeks (currently a CDC-approved regimen),
or 52 weeks.97 The median age was 50 years, and 53% were men.
After 5 years, 1.4% of the placebo group and 0.5% of the 24-week
treatment group developed active TB, for a relative risk of 0.35
(95% CI, 0.24-0.52; number needed to treat, 112). Individuals with
larger fibrotic lesions had a greater risk of developing active TB; the
incidence of active TB in the placebo group was approximately half
as great among individuals with lesions less than 2 cm2 (11.6 per
1000) as among individuals with larger lesions (21.3 per 1000).
There were no deaths attributable to TB in any of the isoniazid
groups; 3 individuals died of TB in the placebo group. One open-
label trial randomized 847 participants to 4months of rifampin or 9
months of isoniazid to compare adverse events and treatment
completion.95 It reported zero deaths from TB in either group, zero
deaths (due to any cause) in the rifampin group, and 1 death in the
isoniazid group.
The PREVENT TB study was an open-label, noninferiority RCT
that randomized 7731 individuals to directly observed once-
weekly rifapentine plus isoniazid for 3 months or to daily self-
administered isoniazidfor9months.96Mostparticipants(89%)were
fromtheUnitedStatesorCanadaandwerehigh-risk individualswith
a positive TST result. Most (71%) had a close contact with a patient
with active TBwithin 2 years; 25%were included solely because of
conversion to skin-test positivity. Risk factors for TB included a his-
tory of incarceration (5.1%), injection-drug use (3.7%), and home-
lessness (27.8%). Data were obtained from the CDC for the subset
ofparticipantsmostdirectly relevant for this review: the6886adults
(18 years or older) who were HIV negative and TST or IGRA posi-
tive. Themedian age for this subsetwas37years; 54.2%weremen,
and 57% were white. For this subset, active TB developed in 5 in-
dividuals in thecombination-therapygroupand 10 individuals in the
isoniazid-only group over 33 months of follow-up. The combina-
tion therapy was found to be noninferior to isoniazid-only treat-
ment. Overall mortality was similar for the 2 groups (30 partici-
pants vs 34 participants, respectively; P = .42).
FourRCTs identifiedascomparing isoniazidwithplacebodidnot
meet all eligibility criteria (mainly because of duration of treatment
or dose as described in the Methods) but were used in sensitivity
analyses (eTable 13 in theSupplement).15-18Sensitivityanalysesusing
data from the 24- and 52-week groups from the IUAT trial and from
these 4 additional RCTs found a relative risk (RR) of 0.31 (95% CI,
0.24-0.41; 36 823 participants) and no statistical heterogeneity in
effects between studies (I2 = 0.0%) (eTable 14 andeFigure4 in the
Supplement).
Harms of Screening
KeyQuestion4.Are thereharmsassociatedwithscreening forLTBI?
Do these harms differ by screening method or strategy? Do these
harms differ by population?
No eligible studies were identified.
Harms of Treatment
KeyQuestion5.Are thereharmsassociatedwith treatment forLTBI
with CDC-recommended pharmacotherapy?
Study characteristics of trials evaluating the harms of treat-
mentarereported inTable2.FiveRCTswere included.94-98Onecom-
pared isoniazid with placebo (n = 27 830)97; 3 compared rifampin
with isoniazid (n = 1327)94,95,98; and1comparedrifapentineplus iso-
niazid with isoniazid alone (n = 6886).96
The IUAT trial (described above) reported theRRs for develop-
ing hepatitis (undefined by study authors) associated with isonia-
zid comparedwith placebo as 3.45 (95%CI, 1.49-7.99) for 12weeks
of treatment, 4.59 (95% CI, 2.03-10.39) for 24 weeks (number
needed to harm [NNH], 279), and 6.21 (95% CI, 2.79-13.79) for 52
weeks. Mortality rates from hepatitis were 0.03% for the 12-week
isoniazid treatment group,0.0%for the24-week treatment group,
and0.01%for the52-weektreatmentgroup(zerodeaths fromhepa-
titis amongplacebo-treatedpatients). Themortality rate fromhepa-
titis was 0.14 per 1000 persons receiving isoniazid (RR, 2.35 [95%
CI,0.12-45.46];NNH,6947). Sensitivity analyses for isoniazid com-
pared with placebo for hepatitis using data from the IUAT trial
(3 treatmentgroupscombined)and3additionalRCTs15,19,20 thatdid
notmeet all eligibility criteria (eTables 13 and 15 in the Supplement)
found an RR of 5.04 (95% CI, 2.50-10.15 [4 studies, 35 161 partici-
pants]) and no statistical heterogeneity among studies (I2 = 0.0%;
P = .63).
In the IUAT trial, discontinuation because of adverse events
was reported for 345 patients (1.8%) receiving isoniazid com-
pared with 84 patients (1.2%) receiving placebo (RR, 1.50 [95%
CI, 1.18-1.89]; NNH, 167). The most common reason was gastroin-
testinal distress (1.2% receiving isoniazid vs 0.9% placebo; RR,
1.33 [95% CI, 1.01-1.75]).
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Three studies provided evidence on harms of rifampin as com-
pared with isoniazid. One open-label RCT conducted in Canada
(n = 116) compared 4 months of rifampin with 9 months of
isoniazid.94A later studybythesameauthors (describedabove) ran-
domized847participants to the same2 treatments.95 Participants
in both studies were 18 years or older with documented LTBI. The
third trial randomized inmates (n = 365) in theSanFranciscoCityand
CountyJailwithLTBIat jail entry to9monthsof isoniazidor4months
of rifampin.98
Rates of hepatotoxicity in these 3 RCTs among individuals re-
ceiving isoniazid were 5.2%,94 3.7%,95 and 11.4%,98 respectively.
Ratesamongrifampin-treatedpatientswere lower (0.0%,0.7%,and
4.4%, respectively). Pooled estimates from these 3 RCTs found a
greater riskofhepatotoxicity forpatients treatedwith isoniazid than
for those treatedwith rifampin (RR,3.29 [95%CI, 1.72-6.28] [3 stud-
ies, 1327participants]) (eFigure5 in theSupplement). All studies re-
ported zero deaths from hepatotoxicity. Rates of discontinuations
because of adverse events were 13.8% (isoniazid) and 3.4%
(rifampin)94; 5.6% (isoniazid) and 3.8% (rifampin)95; and 0.0%
(isoniazid) and 1.1%(rifampin).98Thepooledestimate foundnosta-
tistically significant difference between treatments (RR, 1.61 [95%
CI, 0.57-4.57] [3 studies; n = 1327]). Similar rates of gastrointesti-
nal adverseeventswere reportedamongthe3studies;variousother
harms were reported, but no significant differences between iso-
niazid and rifampin were identified.
ThePREVENTTBtrial (describedabove) reportedratesofgrade
3hepatotoxicity of4.9% in the rifapentineplus isoniazid groupand
5.5% in the isoniazid-only group; corresponding rates of grade 4
hepatotoxicitywere 1.0%and 1.1%, respectively.96TheRR forgrade
3 or 4 hepatotoxicity was 0.90 (95%CI, 0.75-1.08). Mortality from
hepatotoxicitywas reported in 1.0%of patients receiving isoniazid
and 0.8%of patients receiving rifapentine plus isoniazid (RR, 0.83
[95% CI, 0.51-1.35]). Rates of discontinuation because of adverse
events were 5.2% in the rifapentine plus isoniazid group and 4.1%
in the isoniazid-onlygroup.TheRRof treatmentdiscontinuationbe-
causeofadverseevents for rifapentineplus isoniazidvs isoniazidonly
was 1.28 (95% CI, 1.03-1.59). Possible hypersensitivity was re-
ported in 0.5% of patients receiving isoniazid and 4.1% of patients
receiving rifapentine plus isoniazid. The relative risk of possible hy-
persensitivity for rifapentineplus isoniazidvs isoniazidonlywas8.04
(95% CI, 4.88-13.26).
Discussion
Table 3 summarizes the evidence reviewed to inform an updated
USPSTF recommendationonscreening for LTBIwithinprimary care
settings. For thepopulationsandsettingsevaluated, currently avail-
ablescreeningtestsweremoderatelysensitiveand, incountrieswith
low TB burden , highly specific. Treatment with current CDC-
recommended pharmacotherapy regimenswas effective at reduc-
ing theprogression toactiveTB,but treatmentwasassociatedwith
an increased risk for hepatotoxicity.
The applicability of the evidence on accuracy and reliability of
screening tests to primary care practice settings and populations is
uncertain for several reasons. The lack of a direct test for LTBI re-
quires test accuracy studies to beperformed in specific, nonprimary
care–related populations (ie, active, confirmed TB for sensitivity;Ta
bl
e
2.
St
ud
y
Ch
ar
ac
te
ris
tic
so
fR
an
do
m
iz
ed
Cl
in
ic
al
Tr
ia
ls
of
Be
ne
fit
s(
Ke
y
Q
ue
st
io
n
3)
an
d
H
ar
m
s(
Ke
y
Q
ue
st
io
n
5)
of
Tr
ea
tm
en
t(
co
nt
in
ue
d)
So
ur
ce
Po
pu
la
tio
n
TB
Ri
sk
Fa
ct
or
s,
N
o.
(%
)
Ag
e,
y
M
en
,
N
o.
(%
)
Fo
llo
w
-u
p
LT
BI
Co
nf
irm
ed
Co
un
tr
y
(T
B
Bu
rd
en
)a
Q
ua
lit
yb
W
hi
te
et
al
,9
8
20
12
(n
=
36
4
pa
rt
ic
ip
an
ts
)
In
m
at
es
≥1
8
y
di
ag
no
se
d
w
ith
LT
BI
at
Sa
n
Fr
an
ci
sc
o
ja
il
en
tr
y;
33
4
(9
2%
)
no
nw
hi
te
BC
G
va
cc
in
at
io
n
N
R
Fo
re
ig
n-
bo
rn
:2
78
(7
6)
Ja
ile
d
be
fo
re
:2
55
(7
0)
Dr
ug
/a
lc
oh
ol
pr
ob
le
m
:
18
6
(5
1)
<3
5:
25
8
(7
1%
)
≥3
5:
10
6
(2
9%
)
Ye
s(
m
et
ho
d
N
R)
Un
ite
d
St
at
es
(l
ow
)
Fa
ir
Ri
fa
m
pi
n
(6
00
m
g/
d)
×4
to
6
m
o
16
6
(9
2)
16
-2
4
w
k
Is
on
ia
zi
d
(9
00
m
g
tw
ic
e
a
w
k)
×9
to
12
m
o
17
3
(9
4)
36
-5
2
w
k
Ab
br
ev
ia
tio
ns
:H
IV
,h
um
an
im
m
un
od
ef
ic
ie
nc
y
vi
ru
s;
IG
RA
,i
nt
er
fe
ro
n-
ga
m
m
a
re
le
as
e
as
sa
ys
;I
UA
T,
In
te
rn
at
io
na
l
U
ni
on
Ag
ai
ns
tT
ub
er
cu
lo
sis
an
d
Lu
ng
D
ise
as
e;
LT
BI
,l
at
en
tt
ub
er
cu
lo
sis
in
fe
ct
io
n;
N
R,
no
tr
ep
or
te
d;
TB
,t
ub
er
cu
lo
sis
;T
ST
,t
ub
er
cu
lin
sk
in
te
st
.
a
Tu
be
rc
ul
os
is
bu
rd
en
pe
r1
0
0
0
0
0
ac
co
rd
in
g
to
W
or
ld
H
ea
lth
O
rg
an
iz
at
io
n
cl
as
sif
ic
at
io
n:
lo
w
,<
10
ca
se
s;
in
te
rm
ed
ia
te
,1
0
-9
9
ca
se
s;
hi
gh
,>
10
0
ca
se
s.
b
Q
ua
lit
y
as
se
ss
ed
us
in
g
cr
ite
ria
de
ve
lo
pe
d
by
th
e
U
S
Pr
ev
en
tiv
e
Se
rv
ic
es
Ta
sk
Fo
rc
e.
c
N
um
be
ro
fp
ar
tic
ip
an
ts
w
ho
ha
ve
be
en
in
cl
os
e
co
nt
ac
tw
ith
an
in
di
vi
du
al
w
ith
ac
tiv
e
tu
be
rc
ul
os
is
un
sp
ec
ifi
ed
.
d
Al
th
ou
gh
tu
be
rc
ul
os
is
bu
rd
en
in
Ca
na
da
is
lo
w
,5
4%
-5
5%
of
th
e
Ca
na
di
an
pa
rt
ic
ip
an
ts
(n
=
46
2)
w
er
e
bo
rn
in
co
un
tr
ie
sw
ith
hi
gh
tu
be
rc
ul
os
is
in
ci
de
nc
e.
e
D
at
a
ex
tr
ac
te
d
fr
om
su
pp
le
m
en
ta
ld
at
a
(P
.L
oB
ue
,M
D,
D
iv
isi
on
of
Tu
be
rc
ul
os
is
El
im
in
at
io
n,
Ce
nt
er
sf
or
D
ise
as
e
Co
nt
ro
la
nd
Pr
ev
en
tio
n,
w
rit
te
n
co
m
m
un
ic
at
io
n)
fo
re
lig
ib
le
st
ud
y
su
bg
ro
up
(H
IV
-n
eg
at
iv
e
pa
rt
ic
ip
an
ts
w
ith
TS
T
or
IG
RA
co
nf
irm
at
io
n)
.
f
In
cl
us
io
n
cr
ite
ria
in
iti
al
ly
lim
ite
d
to
ag
es
20
-6
4
ye
ar
s,
bu
ta
fe
w
pe
rs
on
sa
re
in
cl
ud
ed
ou
ts
id
e
th
es
e
lim
its
.
g
Fi
br
ot
ic
pu
lm
on
ar
y
le
sio
ns
de
fin
ed
as
w
el
l-d
el
in
ea
te
d
ra
di
og
ra
ph
ic
le
sio
ns
of
pr
ob
ab
le
tu
be
rc
ul
ou
so
rig
in
,
us
ua
lly
in
th
e
up
pe
rh
al
fo
ft
he
lu
ng
,w
hi
ch
ha
d
be
en
st
ab
le
du
rin
g
th
e
ye
ar
pr
io
rt
o
en
tr
y.
Fo
rp
ar
tic
ip
an
ts
,t
he
le
sio
ns
ha
d
be
en
kn
ow
n
to
ex
ist
fo
ra
m
ed
ia
n
of
8
ye
ar
s(
ra
ng
e,
11
m
on
th
st
o
58
ye
ar
s)
.
h
M
ed
ia
n
in
du
ra
tio
n
w
as
15
m
m
(r
an
ge
,6
-9
0
m
m
).
i
Cz
ec
ho
slo
va
ki
a
(lo
w
),
Fi
nl
an
d
(lo
w
),
Ge
rm
an
y
(lo
w
),
H
un
ga
ry
(in
te
rm
ed
ia
te
),
Po
la
nd
(in
te
rm
ed
ia
te
),
Ro
m
an
ia
(in
te
rm
ed
ia
te
),
Yu
go
sla
vi
a
(lo
w
-in
te
rm
ed
ia
te
).
Evidence Report: Primary Care Approaches to Latent TB in Adults US Preventive Services Task Force Clinical Review& Education
jama.com (Reprinted) JAMA September 6, 2016 Volume 316, Number 9 977
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
Ta
bl
e
3.
Su
m
m
ar
y
of
Ev
id
en
ce
:S
cr
ee
ni
ng
an
d
Tr
ea
tm
en
tf
or
La
te
nt
Tu
be
rc
ul
os
is
In
fe
ct
io
n
in
Ad
ul
ts
Ke
y
Q
ue
st
io
n
N
o.
of
St
ud
ie
s
N
o.
of
Pa
rt
ic
ip
an
ts
St
ud
y
De
si
gn
Su
m
m
ar
y
of
Fi
nd
in
gs
(I
nc
lu
di
ng
Co
ns
is
te
nc
y
an
d
Pr
ec
is
io
n)
Ap
pl
ic
ab
ili
ty
Li
m
ita
tio
ns
(I
nc
lu
di
ng
Re
po
rt
in
g
Bi
as
)
Q
ua
lit
y
of
Ev
id
en
ce
Ke
y
qu
es
tio
n
1:
Be
ne
fit
so
f
sc
re
en
in
g
0
N
A
N
A
N
o
st
ud
ie
se
va
lu
at
ed
th
e
di
re
ct
be
ne
fit
of
sc
re
en
in
g
vs
no
sc
re
en
in
g.
N
A
N
A
N
A
Ke
y
qu
es
tio
n
2:
Ac
cu
ra
cy
of
sc
re
en
in
g
w
ith
TS
T
27
a
11
08
3b
O
bs
er
va
tio
na
l
st
ud
ie
s
as
se
ss
in
g
te
st
ac
cu
ra
cy
Se
ns
iti
vi
ty
fo
rd
et
ec
tin
g
in
fe
ct
io
n,
0.
52
us
in
g
15
-m
m
th
re
sh
ol
d
to
0.
79
fo
rb
ot
h
th
e
5-
m
m
an
d
10
-m
m
th
re
sh
ol
ds
;f
in
di
ng
sw
er
e
m
os
tl
y
co
ns
is
te
nt
bu
ti
m
pr
ec
is
e.
Sp
ec
ifi
ci
ty
0.
95
-0
.9
9
fo
ra
ll
th
re
sh
ol
ds
in
lo
w
TB
-b
ur
de
n
co
un
tr
ie
s,
an
d
fin
di
ng
sw
er
e
bo
th
co
ns
is
te
nt
an
d
pr
ec
is
e.
TS
T
us
in
g
M
an
to
ux
pr
oc
ed
ur
e
w
ith
in
te
rm
ed
ia
te
-s
tr
en
gt
h
do
se
of
PP
D.
La
ck
of
di
re
ct
te
st
fo
rL
TB
Ir
eq
ui
re
s
ex
tr
ap
ol
at
io
n
of
te
st
ch
ar
ac
te
ris
tic
sf
ro
m
pa
rt
ic
ip
an
ts
w
ith
ac
tiv
e
TB
(f
or
se
ns
iti
vi
ty
)a
nd
he
al
th
y,
lo
w
-r
is
k
pa
rt
ic
ip
an
ts
(f
or
sp
ec
ifi
ci
ty
).
De
sc
rip
tio
n
of
su
bj
ec
tc
ha
ra
ct
er
is
tic
s
hi
gh
ly
va
ria
bl
e
ac
ro
ss
st
ud
ie
s.
In
de
pe
nd
en
ti
nt
er
pr
et
at
io
n
of
te
st
of
te
n
no
tr
ep
or
te
d.
N
o
ev
id
en
ce
of
re
po
rt
in
g
bi
as
.
Fa
ir
Ke
y
qu
es
tio
n
2:
Ac
cu
ra
cy
of
sc
re
en
in
g
w
ith
IG
RA
56
a
63
58
b
O
bs
er
va
tio
na
l
st
ud
ie
s
as
se
ss
in
g
te
st
ac
cu
ra
cy
Se
ns
iti
vi
ty
fo
rd
et
ec
tin
g
in
fe
ct
io
n,
0.
77
to
0.
90
de
pe
nd
in
g
on
as
sa
y
us
ed
;
fin
di
ng
sw
er
e
co
ns
is
te
nt
an
d
pr
ec
is
e.
Sp
ec
ifi
ci
ty
0.
95
-0
.9
8
de
pe
nd
in
g
on
as
sa
y
us
ed
;f
in
di
ng
sw
er
e
co
ns
is
te
nt
an
d
pr
ec
is
e
in
lo
w
TB
-b
ur
de
n
co
un
tr
ie
s.
IG
RA
sr
eq
ui
re
pr
op
er
sp
ec
im
en
ha
nd
lin
g
pr
io
r
to
as
sa
y.
FD
A-
ap
pr
ov
ed
th
re
sh
ol
d
fo
rp
os
iti
ve
T-
SP
OT
.T
B
IG
RA
te
st
us
ed
in
US
st
ud
ie
sh
ig
he
r
th
an
th
re
sh
ol
d
us
ed
in
no
n-
US
st
ud
ie
s.
Fi
nd
in
gs
fr
om
Q
ua
nt
iF
ER
O
N
IG
RA
sr
ef
le
ct
se
ve
ra
lg
en
er
at
io
ns
of
th
e
as
sa
y,
so
m
e
of
w
hi
ch
m
ay
no
lo
ng
er
be
co
m
m
er
ci
al
ly
av
ai
la
bl
e.
La
ck
of
di
re
ct
te
st
fo
rL
TB
Ir
eq
ui
re
s
ex
tr
ap
ol
at
io
n
of
te
st
ch
ar
ac
te
ris
tic
sf
ro
m
pa
rt
ic
ip
an
ts
w
ith
ac
tiv
e
TB
(f
or
se
ns
iti
vi
ty
)a
nd
he
al
th
y,
lo
w
-r
is
k
pa
rt
ic
ip
an
ts
(f
or
sp
ec
ifi
ci
ty
).
De
sc
rip
tio
n
of
pa
rt
ic
ip
an
t
ch
ar
ac
te
ris
tic
sa
nd
re
po
rt
in
g
of
in
de
te
rm
in
at
e
re
su
lts
hi
gh
ly
va
ria
bl
e
ac
ro
ss
st
ud
ie
s.
In
de
pe
nd
en
ti
nt
er
pr
et
at
io
n
of
te
st
of
te
n
no
tr
ep
or
te
d.
N
o
ev
id
en
ce
of
re
po
rt
in
g
bi
as
.
Fa
ir
Ke
y
qu
es
tio
n
3:
Be
ne
fit
so
f
tr
ea
tm
en
t
3c
(4
m
or
e
in
se
ns
iti
vi
ty
an
al
ys
is
)
35
56
3c
(8
99
3
m
or
e
in
se
ns
iti
vi
ty
an
al
ys
is
)
RC
Ts
IU
AT
tr
ia
lf
ou
nd
th
at
is
on
ia
zi
d
fo
r2
4
w
k
re
du
ce
d
th
e
ris
k
of
de
ve
lo
pi
ng
ac
tiv
e
TB
vs
pl
ac
eb
o
(R
R,
0.
35
at
5
y
[9
5%
CI
,0
.2
4-
0.
52
];
N
N
T,
11
2)
d
.
Da
ta
fr
om
1
la
rg
e
op
en
-l
ab
el
no
ni
nf
er
io
rit
y
tr
ia
le
fo
un
d
th
at
rif
ap
en
tin
e
+
is
on
ia
zi
d
w
as
no
ni
nf
er
io
rt
o
is
on
ia
zi
d
al
on
e.
O
ve
ra
ll,
tr
ia
ls
re
po
rt
ed
lim
ite
d
da
ta
on
de
at
hs
du
e
to
TB
.
Is
on
ia
zi
d
vs
pl
ac
eb
o:
IU
AT
tr
ia
li
nc
lu
de
d
pa
rt
ic
ip
an
ts
w
ith
fib
ro
tic
pu
lm
on
ar
y
le
si
on
sa
nd
≥6
m
m
TS
T.
IU
AT
tr
ia
la
nd
RC
Ts
us
ed
in
se
ns
iti
vi
ty
an
al
ys
es
f
pu
bl
is
he
d
>3
0
y
ag
o.
Ri
fa
pe
nt
in
e
+
is
on
ia
zi
d
vs
is
on
ia
zi
d
al
on
e:
rif
ap
en
tin
e
+
is
on
ia
zi
d
w
as
di
re
ct
ly
ob
se
rv
ed
on
ce
w
ee
kl
y
fo
r3
m
o;
m
os
tp
ar
tic
ip
an
ts
ha
d
a
cl
os
e
co
nt
ac
tw
ith
ac
tiv
e
TB
;2
5%
w
er
e
in
cl
ud
ed
be
ca
us
e
of
re
ce
nt
TS
T
co
nv
er
si
on
.
Is
on
ia
zi
d
vs
pl
ac
eb
o:
St
ud
ie
si
n
se
ns
iti
vi
ty
an
al
ys
is
us
ed
lo
ng
er
du
ra
tio
n
(1
y)
,g
an
d
so
m
e
us
ed
do
se
sl
ow
er
or
hi
gh
er
th
an
cu
rr
en
tly
re
co
m
m
en
de
d.
Ri
fa
pe
nt
in
e
+
is
on
ia
zi
d
vs
is
on
ia
zi
d
al
on
e:
op
en
la
be
l;
si
ng
le
st
ud
y.
N
o
ev
id
en
ce
of
re
po
rt
in
g
bi
as
.
Go
od
(f
ai
rt
o
go
od
fo
r
st
ud
ie
si
n
se
ns
iti
vi
ty
an
al
ys
is
)
Ke
y
qu
es
tio
n
4:
H
ar
m
so
fs
cr
ee
ni
ng
0
N
A
N
A
N
o
st
ud
ie
sw
er
e
id
en
tif
ie
d
th
at
ev
al
ua
te
d
th
e
ha
rm
so
fs
cr
ee
ni
ng
vs
no
sc
re
en
in
g.
N
A
N
A
N
A (
co
nt
in
ue
d)
Clinical Review& Education US Preventive Services Task Force Evidence Report: Primary Care Approaches to Latent TB in Adults
978 JAMA September 6, 2016 Volume 316, Number 9 (Reprinted) jama.com
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
Ta
bl
e
3.
Su
m
m
ar
y
of
Ev
id
en
ce
:S
cr
ee
ni
ng
an
d
Tr
ea
tm
en
tf
or
La
te
nt
Tu
be
rc
ul
os
is
In
fe
ct
io
n
in
Ad
ul
ts
(c
on
tin
ue
d)
Ke
y
Q
ue
st
io
n
N
o.
of
St
ud
ie
s
N
o.
of
Pa
rt
ic
ip
an
ts
St
ud
y
De
si
gn
Su
m
m
ar
y
of
Fi
nd
in
gs
(I
nc
lu
di
ng
Co
ns
is
te
nc
y
an
d
Pr
ec
is
io
n)
Ap
pl
ic
ab
ili
ty
Li
m
ita
tio
ns
(I
nc
lu
di
ng
Re
po
rt
in
g
Bi
as
)
Q
ua
lit
y
of
Ev
id
en
ce
Ke
y
qu
es
tio
n
5:
H
ar
m
so
ft
re
at
m
en
t
5h
(3
m
or
e
in
se
ns
iti
vi
ty
an
al
ys
is
)
36
04
3h
(7
33
1
m
or
e
in
se
ns
iti
vi
ty
an
al
ys
es
)
RC
Ts
Is
on
ia
zi
d
vs
pl
ac
eb
o:
IU
AT
tr
ia
lf
ou
nd
is
on
ia
zi
d
fo
r2
4
w
k
in
cr
ea
se
d
ris
k
of
he
pa
to
to
xi
ci
ty
(R
R,
4.
59
at
5
y
[9
5%
CI
,2
.0
3-
10
.3
9]
,N
N
H
,2
79
)i
an
d
ris
k
of
GI
ad
ve
rs
e
ev
en
ts
(R
R,
1.
33
[9
5%
CI
,1
.0
1-
1.
75
])
vs
pl
ac
eb
o.
H
ep
at
ot
ox
ic
ity
:
0.
14
de
at
hs
/1
00
0
re
ce
iv
in
g
is
on
ia
zi
d
(R
R,
2.
35
[9
5%
CI
,0
.1
2-
45
.4
6]
).
j
Is
on
ia
zi
d
vs
rif
am
pi
n:
co
ns
is
te
nt
fin
di
ng
st
ha
t
ris
k
of
he
pa
to
to
xi
ci
ty
gr
ea
te
rw
ith
is
on
ia
zi
d
th
an
w
ith
rif
am
pi
n
(p
oo
le
d
RR
fr
om
3
RC
Ts
,
3.
29
[9
5%
CI
,1
.7
2-
6.
28
])
.
Ri
fa
pe
nt
in
e
+
is
on
ia
zi
d
vs
is
on
ia
zi
d
al
on
e:
da
ta
fr
om
1
no
ni
nf
er
io
rit
y
tr
ia
le
fo
un
d
RR
of
0.
90
(9
5%
CI
,0
.7
5-
1.
08
)f
or
he
pa
to
to
xi
ci
ty
an
d
in
cr
ea
se
d
ris
k
of
po
ss
ib
le
hy
pe
rs
en
si
tiv
ity
w
ith
rif
ap
en
tin
e
+
is
on
ia
zi
d
(R
R,
8.
04
[9
5%
CI
,
4.
88
-1
3.
26
])
.
Is
on
ia
zi
d
vs
pl
ac
eb
o:
IU
AT
tr
ia
li
nc
lu
de
d
pa
rt
ic
ip
an
ts
w
ith
fib
ro
tic
pu
lm
on
ar
y
le
si
on
sa
nd
≥6
-m
m
TS
T.
IU
AT
tr
ia
la
nd
RC
Ts
us
ed
in
se
ns
iti
vi
ty
an
al
ys
es
k
pu
bl
is
he
d
>3
0
y
ag
o.
Is
on
ia
zi
d
vs
rif
am
pi
n:
pa
rt
ic
ip
an
ts
ha
d
po
si
tiv
e
TS
T
in
2
tr
ia
ls
;t
he
ot
he
rt
ria
li
nc
lu
de
d
in
m
at
es
di
ag
no
se
d
w
ith
LT
BI
at
ja
il
en
tr
y.
Ri
fa
pe
nt
in
e
+
is
on
ia
zi
d
vs
is
on
ia
zi
d
al
on
e:
rif
ap
en
tin
e
+
is
on
ia
zi
d
w
as
di
re
ct
ly
ob
se
rv
ed
on
ce
w
ee
kl
y
fo
r3
m
o;
m
os
tp
ar
tic
ip
an
ts
ha
d
a
cl
os
e
co
nt
ac
tw
ith
ac
tiv
e
TB
;2
5%
w
er
e
in
cl
ud
ed
be
ca
us
e
of
re
ce
nt
TS
T
co
nv
er
si
on
.
Is
on
ia
zi
d
vs
pl
ac
eb
o:
H
ar
m
as
ce
rt
ai
nm
en
tt
ec
hn
iq
ue
sn
ot
w
el
ld
es
cr
ib
ed
;v
er
y
fe
w
de
at
hs
du
e
to
he
pa
to
to
xi
ci
ty
(r
ar
e
ev
en
ts
).
Is
on
ia
zi
d
vs
rif
am
pi
n:
2
tr
ia
ls
w
er
e
op
en
-l
ab
el
,1
tr
ia
lh
ad
hi
gh
at
tr
iti
on
.
Ri
fa
pe
nt
in
e
+
is
on
ia
zi
d
vs
is
on
ia
zi
d
al
on
e:
op
en
la
be
l;
si
ng
le
st
ud
y;
hi
gh
ov
er
al
la
tt
rit
io
n.
N
o
ev
id
en
ce
of
re
po
rt
in
g
bi
as
.
Fa
ir
Ab
br
ev
ia
tio
ns
:F
DA
,U
S
Fo
od
an
d
D
ru
g
Ad
m
in
ist
ra
tio
n;
GI
,g
as
tr
oi
nt
es
tin
al
;I
GR
A,
in
te
rf
er
on
-g
am
m
a
re
le
as
e
as
sa
y;
IU
AT
,I
nt
er
na
tio
na
lU
ni
on
Ag
ai
ns
tT
ub
er
cu
lo
sis
;L
TB
I,
la
te
nt
tu
be
rc
ul
os
is
in
fe
ct
io
n;
N
A,
no
ta
pp
lic
ab
le
;
N
N
H
,n
um
be
rn
ee
de
d
to
ha
rm
;N
N
T,
nu
m
be
rn
ee
de
d
to
tr
ea
t;
PP
D,
pu
rif
ie
d
pr
ot
ei
n
de
riv
at
iv
e;
RC
T,
ra
nd
om
iz
ed
cl
in
ic
al
tr
ia
l;
RR
,r
el
at
iv
e
ris
k;
TS
T,
tu
be
rc
ul
in
sk
in
te
st
.
a
U
ni
qu
e
st
ud
ie
sc
on
tr
ib
ut
in
g
to
es
tim
at
es
of
se
ns
iti
vi
ty
or
sp
ec
ifi
ci
ty
or
bo
th
.
b
U
ni
qu
e
pa
rt
ic
ip
an
ts
an
al
yz
ed
to
ge
ne
ra
te
es
tim
at
es
of
se
ns
iti
vi
ty
or
sp
ec
ifi
ci
ty
.S
om
e
st
ud
ie
sa
na
ly
ze
d
th
e
sa
m
e
pa
rt
ic
ip
an
ts
in
ev
al
ua
tio
n
of
di
ffe
re
nt
te
st
th
re
sh
ol
ds
.
c
In
cl
ud
es
27
83
0
fr
om
th
e
IU
AT
tr
ia
lo
fi
so
ni
az
id
vs
pl
ac
eb
o,
84
7
fr
om
an
RC
T
of
iso
ni
az
id
vs
rif
am
pi
n,
an
d
68
86
fr
om
tr
ia
lo
fr
ifa
pe
nt
in
e
+
iso
ni
az
id
vs
iso
ni
az
id
al
on
e.
In
th
e
IU
AT
tr
ia
l,
th
e
on
ly
tr
ia
lm
ee
tin
g
al
le
lig
ib
ili
ty
cr
ite
ria
fo
rK
ey
Q
ue
st
io
n
3
th
at
co
m
pa
re
d
iso
ni
az
id
w
ith
pl
ac
eb
o,
69
65
of
th
e
pa
rt
ic
ip
an
ts
w
er
e
tr
ea
te
d
w
ith
a
Ce
nt
er
s
fo
rD
ise
as
e
Co
nt
ro
la
nd
Pr
ev
en
tio
n
(C
D
C)
–a
pp
ro
ve
d
re
gi
m
en
(is
on
ia
zi
d,
30
0
m
g
×2
4
w
ee
ks
).
d
D
at
a
sh
ow
n
ar
e
ba
se
d
on
th
e
IU
AT
tr
ia
l.
Th
e
re
la
tiv
e
ris
ks
fo
rt
he
ot
he
rI
UA
T
tr
ea
tm
en
tg
ro
up
sf
or
de
ve
lo
pi
ng
ac
tiv
e
TB
co
m
pa
re
d
w
ith
pl
ac
eb
o
w
er
e
0.
79
(9
5%
CI
,0
.5
8-
1.0
6)
fo
r1
2
w
ee
ks
of
iso
ni
az
id
an
d
0.
25
(9
5%
CI
,
0.
16
-0
.3
9)
fo
r5
2
w
ee
ks
of
iso
ni
az
id
.O
ur
se
ns
iti
vi
ty
an
al
ys
is
in
cl
ud
in
g
th
e
IU
AT
tr
ia
lp
lu
s4
ad
di
tio
na
lR
CT
sw
ith
fo
llo
w
-u
p
ra
ng
in
g
fr
om
2
to
10
ye
ar
sf
ou
nd
a
sim
ila
rr
isk
(p
oo
le
d
RR
,0
.3
1[
95
%
CI
,0
.2
4-
0.
41
])
.T
ria
ls
us
ed
in
th
e
se
ns
iti
vi
ty
an
al
ys
is
w
er
e
co
ns
ist
en
t(
I2
=
0
%
)a
nd
pr
ec
ise
.
e
D
at
a
fr
om
1o
pe
n-
la
be
ln
on
in
fe
rio
rit
y
tr
ia
lt
ha
tr
an
do
m
iz
ed
77
31
in
di
vi
du
al
s;
w
e
ob
ta
in
ed
da
ta
fr
om
th
e
CD
C
fo
r
th
is
ta
bl
e
on
th
e
su
bs
et
of
pa
rt
ic
ip
an
ts
m
os
td
ire
ct
ly
re
le
va
nt
fo
rt
hi
sr
ev
ie
w
:t
he
68
86
ad
ul
ts
(
18
ye
ar
s)
w
ho
w
er
e
H
IV
ne
ga
tiv
e
an
d
w
er
e
TS
T
or
IG
RA
po
sit
iv
e.
Fi
nd
in
gs
w
er
e
re
as
on
ab
ly
pr
ec
ise
;c
on
sis
te
nc
y
w
as
no
t
ap
pl
ic
ab
le
(s
in
gl
e
st
ud
y)
.
f
Tr
ia
ls
in
se
ns
iti
vi
ty
an
al
ys
is
en
ro
lle
d
ho
us
eh
ol
d
co
nt
ac
ts
of
pe
rs
on
sw
ith
ac
tiv
e
TB
,v
et
er
an
sw
ith
in
ac
tiv
e
pu
lm
on
ar
y
TB
,i
nd
iv
id
ua
ls
re
sid
in
g
in
m
en
ta
lin
st
itu
tio
ns
,a
nd
m
ili
ta
ry
m
em
be
rs
ex
po
se
d
to
pe
rs
on
s
w
ith
ac
tiv
e
TB
.
g
N
o
lo
ng
er
a
CD
C-
re
co
m
m
en
de
d
tr
ea
tm
en
tr
eg
im
en
.
h
In
cl
ud
es
27
83
0
fr
om
th
e
IU
AT
tr
ia
lo
fi
so
ni
az
id
vs
pl
ac
eb
o,
13
27
fr
om
3
tr
ia
ls
of
iso
ni
az
id
vs
rif
am
pi
n,
an
d
68
86
fr
om
a
tr
ia
lo
fr
ifa
pe
nt
in
e
+
iso
ni
az
id
vs
iso
ni
az
id
al
on
e.
i
D
at
a
sh
ow
n
ar
e
ba
se
d
on
th
e
IU
AT
tr
ia
l;
ou
rs
en
sit
iv
ity
an
al
ys
is
in
cl
ud
in
g
th
e
IU
AT
tr
ia
lp
lu
s3
ad
di
tio
na
lR
CT
s
fo
un
d
a
sim
ila
rr
isk
(p
oo
le
d
RR
,5
.0
4
[9
5%
CI
,2
.5
0
-10
.15
],
I2
=
0
%
);
po
ol
ed
es
tim
at
e
in
cl
ud
es
co
m
bi
ne
d
da
ta
fr
om
al
l3
iso
ni
az
id
st
ud
y
gr
ou
ps
(1
2
w
ee
ks
,2
4
w
ee
ks
,5
2
w
ee
ks
)i
n
th
e
IU
AT
tr
ia
l.
Tr
ia
ls
us
ed
in
th
e
se
ns
iti
vi
ty
an
al
ys
is
w
er
e
co
ns
ist
en
t,
bu
to
ve
ra
llp
oo
le
d
es
tim
at
e
w
as
im
pr
ec
ise
.
j
Th
er
e
w
er
e
0
de
at
hs
du
e
to
he
pa
to
to
xi
ci
ty
in
th
e
IU
AT
tr
ia
lp
la
ce
bo
gr
ou
p.
O
ne
ad
di
tio
na
lR
CT
us
ed
in
se
ns
iti
vi
ty
an
al
ys
is
fo
rt
hi
so
ut
co
m
e
re
po
rt
ed
0
de
at
hs
fr
om
he
pa
to
to
xi
ci
ty
in
ei
th
er
th
e
iso
ni
az
id
or
pl
ac
eb
o
gr
ou
p.
k
Tr
ia
ls
in
se
ns
iti
vi
ty
an
al
ys
is
en
ro
lle
d
em
pl
oy
ee
si
n
a
U
S
ho
sp
ita
l,
in
di
vi
du
al
sm
ee
tin
g
Am
er
ic
an
Th
or
ac
ic
So
ci
et
y
cr
ite
ria
re
fe
rr
ed
to
a
U
S
m
ili
ta
ry
m
ed
ic
al
ce
nt
er
,a
nd
ve
te
ra
ns
w
ith
in
ac
tiv
e
pu
lm
on
ar
y
TB
.
Evidence Report: Primary Care Approaches to Latent TB in Adults US Preventive Services Task Force Clinical Review& Education
jama.com (Reprinted) JAMA September 6, 2016 Volume 316, Number 9 979
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
healthy populations with low TB risk for specificity). Estimates for
specificity were lower in studies conducted with populations from
countries with intermediate TB burden, specifically Turkey and
South Korea. This could be the result of unintentional inclusion of
participants with unknown past TB exposure, inclusion of BCG-
vaccinatedparticipants, or other factors that affect the administra-
tion or interpretation of tests in these countries. The studies of
screening tests in this reviewdidnot consistently report comorbidi-
tiesof thestudypopulation tested, andalthoughstudies frompopu-
lations with more than 25% HIV-infected individuals were ex-
cluded,patientswithactiveTBoftenhaveunderlyingcomorbidities
related to immunosuppression. The extent to which sensitivity of
tests isbluntedby thisunderlying immunosuppression isnotknown
andmayresult in lowerestimates for sensitivity thanwouldbe found
inpopulationswith latent infection. Conversely, thepresenceof ac-
tive TB diseasemay result inmore host sensitization, so this popu-
lation may overestimate the true sensitivity of the tests for latent
infection.Although7studies forKQ2mayhave included 15-, 16-, and
17-year-olds,26,34,35,42,67,70,77 the scope of this review did not in-
clude children and adolescents, and so findings should not be gen-
eralized to this population.
Theevidenceoneffectivenessof treatment for LTBI comespri-
marily from the IUAT trial. It enrolled participants with pulmonary
fibrotic lesions, a group thought to be at the highest risk for pro-
gression to active TB. It also found that individuals with smaller le-
sions progressed to active TB at lower rates than those with larger
lesions. Thus, estimates of treatment effectivenessmay represent
theupperboundsof effectiveness, andeffectivenessmaybe lower
inotherpopulations. Theevidenceonharmssuggests anRRof4.59
for hepatotoxicity with 6 months of isoniazid compared with pla-
ceboandanRRof 3.29 comparedwith rifampin.Deathsbecauseof
hepatotoxicity were rare across all studies, so estimates were im-
precise. In the IUAT study, all 3 participants who died of hepatitis
had continued to take isoniazid after liver abnormalities were
recognized.97 The rateof treatmentdiscontinuationbecauseof ad-
verse events was modestly increased for isoniazid compared with
placebo based on a single study but was no different between iso-
niazid and rifampinbasedonapooledestimate froma3-studybody
of evidence that was somewhat inconsistent and imprecise.
Isoniazidwasestablishedas aneffective treatmentof LTBI sev-
eral decades ago, and CDC treatment recommendations have
evolvedbasedon studies comparing shorter durations andalterna-
tive regimens against the standard isoniazid regimen to reduce
harms, improve adherence, or both, rather than to assess efficacy.
Given that treatment of LTBI has been the standard of care for de-
cades, contemporary data for estimating efficacy or effectiveness
among untreated populations are not available. Furthermore, over
time the prevalence of active TB has declined, yet the prevalence
of resistant strains among those infected has increased. Thus, the
applicability of treatment evidence from before the current era is
unclear. In addition, proponents for screening suggest benefits
on outcomes related to TB transmission and through case-finding
of active TB that occurs during screening. However, no studies
meeting eligibility criteria that reported these outcomes were
identified.
This reviewhad several limitations. A substantial amount of sta-
tistical heterogeneitywas identified in someof thepooledestimates
of test accuracy; however, this heterogeneity is unlikely to be clini-
cally relevant and can be explained by the number of included stud-
ieswith largesamplesizesandpreciseestimates,aphenomenonthat
has beendescribed asproducing elevated I2 estimates.99,100 The re-
viewexcludedtreatmentsnot recommendedbytheCDCandalsoex-
cluded several populations at highest risk of TB (eg, individuals with
HIV),asthescopeofthereviewwas limitedtogenerallyhealthyadults
in primary care settings. Although the scope of the review was nar-
row, the findings are consistent with those from several other re-
views of test characteristics and treatment that included broader
populations and settings.101-105
Conclusions
No studies evaluated the benefits and harms of screening com-
pared with no screening. Both the TST and IGRAs are moderately
sensitive and highly specific within countries with low TB burden.
Treatment reduced the risk of active TB among the populations in-
cluded inthis review. Isoniazid isassociatedwithhigher ratesofhepa-
totoxicity than placebo or rifampin.
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